# Structuring milestone-based funding and pharma partnerships
A biotech with twelve employees and one promising molecule signs a deal with a global pharma company. The upfront payment lands: enough to fund three years of work. But the biotech gives up no board seats and issues no new shares. How?
This is the option-to-license structure, and it is one of the most important financing tools in drug development. Let us dissect how it works and why it lets small companies survive.
Drug development is expensive and slow. Moving one drug from lab to market can cost well over $1 billion (a widely cited estimate, though figures vary a lot) and take ten to fifteen years.
Most biotechs have no revenue. They burn cash for years before knowing if their science works. Traditional equity financing means selling shares to raise money, which dilutes existing owners (reduces their ownership percentage).
So biotechs look for non-dilutive capital: money that does not require giving up equity. Pharma partnerships are a major source.
The partnership matches these needs.
Let us build a representative structure. The numbers below are illustrative, not from a specific deal, but the shape mirrors real agreements you can find in company press releases.
Pharma pays the biotech a lump sum at signing. Say $30 million.
This is non-refundable and non-dilutive. The biotech keeps full ownership. The cash funds early research, often exactly the runway the biotech needs to reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → the next data point.
Here is the clever part. Pharma does not license the drug yet. Instead it buys an option: the right, but not the obligation, to license the drug later, usually after a specific result (for example, positive Phase 1 data, the first stage of human trials that tests safety).
Pharma pays a smaller sum for this option, or bundles it into the upfront. In exchange, pharma gets to wait and see the data before committing big money.
Why does the biotech accept this? Because the alternative, financing a Phase 1 trial through equity, might cost more in ownership than the option costs in upside.
If pharma exercises the option, milestone payments begin. These are payments triggered by hitting specific goals:
A deal might list total milestones of, say, $800 million. That headline number (often called biobucks in the industry) is the sum of everything that could be paid if every milestone hits. In reality most drugs fail, so the full amount is rarely paid. Treat headline totals with skepticism.
If the drug reaches market, the biotech earns royalties: a percentage of net sales, often in the high single digits to low teens, sometimes tiered so the rate rises as sales grow.
Royalties are the long-tail reward. On a blockbuster drug, they can dwarf every milestone combined.
Think of the deal as shifting risk to whoever can bear it best.
Risk transfer. The biotech offloads the enormous cost and risk of late-stage trials onto pharma. If the drug fails in Phase 3, pharma absorbs most of the sunk cost.
Staged capital. Money arrives as the science is validated. Each milestone is a checkpoint. The biotech does not need to raise its entire lifetime budget upfront.
Optionality has value. For pharma, the option limits downside. It pays a modest sum now and only commits large capital once early data reduces uncertainty. This is real options thinking applied to drug development. For a solid primer on the concept, see Investopedia on real options.
No dilution. The founders and early venture investors keep their ownership. If the drug succeeds, their stake is worth far more than if they had sold shares to fund the trials themselves.
🎬 [VIDEO: "How Pharma Licensing Deals Work" — youtube.com — a plain-English walkthrough of upfronts, milestones, and royalties in biotech partnerships]
When you see a partnership announced, do not anchor on the headline biobucks number. Ask:
The upfront is guaranteed cash. Milestones are contingent (they only pay if goals are hit). A deal with $30 million upfront and $800 million in milestones is very different from one with $300 million upfront and $530 million in milestones, even though both "total" $830 million.
Early milestones (Phase 1, Phase 2) are more likely to be paid than late ones. Discount the later payments heavily in your head. A commercial milestone tied to $1 billion in sales is a lottery ticket, not a plan.
Once pharma exercises the option, it usually runs the program. The biotech may lose control over timing, trial design, and strategy. That loss of control is part of the price.
A 5% royalty and a 15% royalty on a blockbuster are the difference between a modest outcome and a company-defining one. The rate matters enormously on the rare drugs that succeed.
You can read real examples in the press releases and SEC filings of public biotechs. The SEC EDGAR database lets you search filings for free; look for the 8-KKThe average number of new users each existing user generates through referrals. Above 1.0, growth compounds on itself and becomes exponential.View full definition → filed when a partnership is announced.
Knowledge check
1. Why do biotechs actively seek non-dilutive capital rather than relying solely on traditional equity financing?
2. In the opening scenario, the biotech receives a large upfront payment but gives up no board seats and issues no new shares. What does this illustrate about the option-to-license structure?
3. Why does large pharma often prefer to buy innovation from small biotechs rather than develop it entirely in-house?
4. Select ALL correct answers about why the upfront payment in an option-to-license deal is valuable to a small biotech.
Select all the correct answers.
5. Select ALL correct answers describing the structural mismatch that an option-to-license partnership resolves.
Select all the correct answers.
Option-to-license is not the only structure. Know the neighbors.
Full acquisition of rights. Pharma licenses the drug outright now, with a bigger upfront and no wait-and-see option. More cash today, but pharma pays a premium for taking on more risk earlier, so it happens less at very early stages.
Co-development and profit share. Instead of royalties, the two firms split development costs and future profits. The biotech keeps more upside but must fund its share of expensive trials, which reinvites the cash problem.
Regional deals. The biotech licenses rights in one territory (say, Asia) while keeping others (US and Europe). This raises cash while preserving upside in the biggest markets.
More cash upfront usually means less upside later. More upside later usually means more risk and cost borne now. Every structure sits somewhere on that spectrum.
A biotech's choice depends on its cash position, its conviction in the science, and its investors' patience. A company running low on runway may take a worse long-term deal for guaranteed cash today. That is a survival decision, not a failure.
Investors value these deals using risk-adjusted net present value (rNPV): they estimate each future payment, multiply it by the probability the drug reaches that stage, and discount it back to today's dollars.
Probabilities of success are brutal. Historically, only a small fraction of drugs entering Phase 1 ever reach approval (industry studies often cite roughly 10%, though it varies widely by disease area). That is why the guaranteed upfront carries so much weight in any honest valuation.
This is analysis, not investment advice. Real deals require legal and financial professionals.